Vazalore Generic: When Will Generic Aspirin Be Available?

Dr. Brian Staiger, PharmD, BCPS

This page is aggregated from FDA records, court filings and company announcements. Coded and designed by

Updated October 9, 2026 How we build our data

Vazalore Generic at a Glance

Four quick answers from FDA records and our estimate.

  1. When is the first generic expected? September 2032 About 6 years away Why then?
  2. Has the FDA approved a generic? Not yet None in the FDA’s records yet Why not yet?
  3. When does the last patent end? September 2032 4 patents listed with the FDA
  4. Can you buy a generic today? Not yet No company lists one for sale

Explains

PharmD, BCPS · Clinical pharmacist Updated

Generic aspirin is expected to be available in September 2032, about 6 years away. None is for sale yet.

Why September 2032?

It is when Vazalore’s patents 9,216,150 and 9,226,892 end. They cover the product’s formulation and a way of using it, and once they end, generics can go on sale as soon as the FDA approves them. We rate it toss-up: still unsettled. Just as likely to slip as to hold.

Why hasn’t the FDA approved a generic yet?

That is normal before a launch. The FDA usually can’t give a generic its final approval while a patent or exclusivity still blocks it, so final approval often comes close to the day the generic can be sold. No company holds a “tentative” approval yet either (the FDA’s word for a generic that is ready but still blocked).

Will the generic cost less?

Usually, but no company is recorded as having applied to make one yet, and a single company usually brings only a modest drop. See the price pattern

What should I do now?

Keep taking Vazalore as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you

Our month is only an estimate based on available information, so we never name a day.

Vazalore by the Numbers

Reason
Patent expiresA patent that protects the brand runs out. After that, approved generics can be sold.
How sure
Toss-up Still unsettled. Just as likely to slip as to hold.
Price competition
None filed yet No filers on record
Brand sales
Sales not reported
  • FDA approved 2013 January 2013 FDA Orange Book
  • Patents listed 4 last runs to September 2032 FDA Orange Book

Vazalore’s Road to a Generic

Vazalore has had the market to itself since the FDA approved it in January 2013 (Plx Pharma Inc). Its 4 listed patents run to September 2032.

The first generic of Vazalore is expected in September 2032.

Why that month: patents 9,216,150 and 9,226,892, on the product’s formulation and a way of using it, end then.

Brand alone on the market Since FDA approval, January 2013
Patent 9,216,150 Expires September 2032 The patent behind the expected month of generic availability
Patent 9,226,892 Expires September 2032 The patent behind the expected month of generic availability
Patent 10,646,431 Expires September 2032
Patent 10,786,444 Expires September 2032
Brand alone on the market Patent on the formulation Patent on a use First generic expected Swipe the chart sideways to see every year.

Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.

Vazalore Patents and FDA Protections

Every patent and exclusivity the FDA Orange Book lists for Vazalore’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.

The one that matters for a generic launch: patents 9,216,150 and 9,226,892, which end in September 2032, the month the first generic is expected.

Patents listed with the FDA (4)
PatentWhat it coversProtects untilStatus
9,216,150 Sets the expected month of generic availability The product’s formulation September 2032 Active
9,226,892 Sets the expected month of generic availability A way of using it (U-1733, U-1731, U-1732) September 2032 Active
10,646,431 The product’s formulation September 2032 Active
10,786,444 A way of using it (U-3559) September 2032 Active

Source: FDA Orange Book, application 203697. Patent numbers open the patent on Google Patents.

Who Is Lined Up to Make Generic Aspirin

Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.

1

Applied to the FDA

No company is recorded as having applied to the FDA to make a generic Vazalore yet.

2

Approved by the FDA

Not yet. The FDA has not approved a generic aspirin. Final approval often comes close to the day a generic can be sold.

3

For Sale in Pharmacies

Not yet. No company lists a generic aspirin for sale with the FDA.

Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).

Vazalore Price: What Pharmacies Pay and What Generics Usually Do

What a Generic Could Cost

How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Vazalore, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).

Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.

Vazalore Strengths and Forms

StrengthFormHow it is takenApprovedStatus
325MGCapsuleOralJanuary 2013Over the counter reference product
81MGCapsuleOralFebruary 2021Over the counter reference product

Source: FDA Orange Book, Plx Pharma Inc. Listed for sale today by PLx Pharma Inc (FDA NDC Directory).

Vazalore NDC Codes and Packages

Each Vazalore package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.

Vazalore packages (4)
NDCProductPackageCompany
73089-0081-1281 mg/81mg capsuleblister pack of 81 mgPLx Pharma Inc
73089-0081-1481 mg/81mg capsulecarton of 81 mgPLx Pharma Inc
73089-0081-2181 mg/81mg capsulebottle of 81 mgPLx Pharma Inc
73089-0325-21325 mg/325mg capsulebottle of 325 mgPLx Pharma Inc

Source: the FDA NDC Directory, current listings only. Only packages sold under Vazalore’s own FDA approval (NDA 203697) are listed, never a generic. Some codes belong to companies that repackage Vazalore: it is the same medicine in a different package.

What a Generic Vazalore Means for You

Nothing Changes Until It Is in Pharmacies

Until a generic is actually for sale, keep filling Vazalore as usual. When one arrives, there is nothing you need to sign up for.

Your Pharmacy May Switch You Automatically

Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.

It Will Probably Look Different

US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.

Your Insurance May Change Too

Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.

Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Vazalore”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.

Questions people ask about Vazalore

Is there a generic for Vazalore right now?

No. As of October 9, 2026 no generic aspirin is listed for sale in the FDA NDC Directory.

When will Vazalore go generic?

September 2032 is the expected month, and that is toss-up but not certain. It is when Vazalore’s patents 9,216,150 and 9,226,892 end. They cover the product’s formulation and a way of using it, and once they end, generics can go on sale as soon as the FDA approves them.

Will generic aspirin be the same as Vazalore?

Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.

How much will the generic cost?

Nobody can say for sure before launch. No company is recorded as having applied to the FDA to make one yet, and a single company usually brings only a modest drop.

Has the FDA approved a generic Vazalore?

Not yet. The FDA Orange Book lists no approved generic version of Vazalore.

When does the Vazalore patent expire?

The FDA Orange Book lists 4 patents for Vazalore; the last runs to September 2032. The one behind the expected month is patents 9,216,150 and 9,226,892, which end in September 2032. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (September 2032) weighs all of that.

Changes to This Projection

  • First generic expected September 2032 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.

Every change to the expected month is logged here with the month we saw it.

Also Going Generic

All upcoming generics

About Vazalore

Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.